WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan · Delayed Price · Currency is TWD 73.50
+0.60 (0.82%)
Aug 26, 2026, 1:13 PM CST
WeLeader Biomedical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,343 | 3,338 | 3,243 | - | - | - | |
Market Cap Growth | 6.06% | 2.93% | - | - | - | - |
Enterprise Value | 4,199 | 3,902 | 3,845 | - | - | - |
Last Close Price | 73.50 | 69.31 | 69.59 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.55 | 16.01 | 19.05 | - | - | - |
PS Ratio | 2.76 | 3.01 | 3.27 | - | - | - |
PB Ratio | 2.78 | 2.65 | 3.57 | - | - | - |
P/TBV Ratio | 2.80 | 2.65 | 3.59 | - | - | - |
P/FCF Ratio | 18.14 | 33.20 | 30.01 | - | - | - |
P/OCF Ratio | 10.16 | 10.66 | 11.63 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.47 | 3.52 | 3.88 | - | - | - |
EV/EBITDA Ratio | 9.54 | 13.48 | 15.83 | - | - | - |
EV/EBIT Ratio | 13.55 | 14.94 | 17.96 | - | - | - |
EV/FCF Ratio | 22.79 | 38.80 | 35.59 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.82 | 0.68 | 0.88 | 0.74 | 1.09 | 0.79 |
Debt / EBITDA Ratio | 2.22 | 2.21 | 2.47 | 2.07 | 2.30 | 1.14 |
Debt / FCF Ratio | 5.31 | 8.48 | 7.37 | 5.34 | - | 1.30 |
Net Debt / Equity Ratio | 0.71 | 0.41 | 0.64 | 0.62 | 0.91 | 0.46 |
Net Debt / EBITDA Ratio | 2.49 | 1.79 | 2.41 | 2.29 | 2.60 | 0.99 |
Net Debt / FCF Ratio | 4.65 | 5.16 | 5.41 | 4.45 | -1.56 | 0.76 |
Asset Turnover | 0.52 | 0.50 | 0.53 | 0.56 | 0.83 | - |
Inventory Turnover | 6.15 | 6.81 | 8.00 | 9.71 | 12.54 | - |
Quick Ratio | 1.08 | 1.52 | 1.04 | 0.94 | 0.89 | 1.13 |
Current Ratio | 1.55 | 1.81 | 1.26 | 1.12 | 1.04 | 1.29 |
Return on Equity (ROE) | 21.80% | 19.23% | 19.41% | 20.41% | 30.64% | - |
Return on Assets (ROA) | 8.34% | 7.34% | 7.18% | 7.43% | 9.80% | - |
Return on Invested Capital (ROIC) | 13.55% | 12.76% | 11.84% | 11.97% | 17.70% | 20.43% |
Return on Capital Employed (ROCE) | 15.00% | 13.00% | 14.00% | 14.90% | 16.80% | 25.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.46% | 6.25% | 5.25% | - | - | - |
FCF Yield | 5.51% | 3.01% | 3.33% | - | - | - |
Dividend Yield | 5.77% | 5.92% | 4.84% | - | - | - |
Payout Ratio | 74.81% | 73.45% | 56.18% | 19.54% | 6.35% | 21.14% |
Buyback Yield / Dilution | -15.19% | -11.38% | -1.55% | -35.00% | -8.28% | - |
Total Shareholder Return | -9.41% | -5.46% | 3.29% | -35.00% | -8.28% | - |